ECS Botanics Sustains Cash Flow and Expands Exports to Germany and New Zealand

Consistent Cash Flow Performance Amid Industry Headwinds

ECS Botanics Holdings Ltd (ASX:ECS) has delivered a third consecutive quarter of positive operating cash flow, recording $118,000 in Q3 FY26 from cash receipts of $4.5 million. This steady cash generation comes despite a significant 28.5% contraction in the Australian medicinal cannabis market during the latter half of 2025, attributed to increased regulatory enforcement targeting high-volume prescribers and clinics. ECS’s ability to maintain stable revenue of $4.81 million underscores its resilience and operational discipline in a challenging environment.

The company’s shift toward higher-margin branded products continues to pay dividends, with branded B2C sales rising 55% year-on-year to $3.4 million, now representing approximately 71% of total revenue. This growth is supported by expanded sales across capsules, OzSun products, and VESIsorb-based formulations, alongside the launch of the “Aussie Smalls” range targeting the value segment and optimising inventory utilisation. ECS’s disciplined cost management and improved gross margins have underpinned the positive cash flow trend, building on momentum from earlier quarters, including a return to profitability in H1 FY26 driven by branded growth and infrastructure investments return to profitability.

International Expansion Gains Traction

ECS is actively broadening its international footprint, marking key milestones in its export strategy. Initial OzSun flower shipments have cleared regulatory testing in Germany, with commercial volumes expected this quarter. These products will be distributed nationally through Nimbus Health’s pharmacy network and digital platform, offering ECS scalable access to Europe’s largest medicinal cannabis market. This follows the strategic partnership with Nimbus Health announced earlier in the year, positioning ECS to leverage its EU-GMP certified production capacity without additional cost German distribution deal.

In New Zealand, ECS is preparing to dispatch its first commercial shipment of medicinal cannabis oils to partner NUBU Pharmaceuticals. The initial balanced THC:CBD oil represents a significant step in diversifying ECS’s product formats and export markets. The companies plan to expand the oil portfolio shortly, enhancing NUBU’s KIKUYA brand presence. This milestone coincides with the fifth anniversary of the ECS-NUBU partnership, highlighting a deepening collaboration that now spans multiple product categories.

Cultivation Resilience and Product Pipeline Progress

On the cultivation front, ECS’s outdoor program in Northwest Victoria is progressing well despite a spell of extreme heat exceeding 40°C. The company’s regenerative farming techniques, including mulch, living ground cover, and overhead irrigation, have bolstered plant health and resilience. Early indications suggest flower quality from new cultivars is outperforming prior seasons, supported by improved harvesting methods. This bodes well for both domestic supply and export commitments.

Product innovation remains a focus, with the AVANI AVA THC:CBD pessary scheduled for launch in early May. The launch will be supported by targeted prescriber education, including a national medical science liaison program and a clinical webinar led by Medical Advisory Board member Dr Charlotte Middleton. ECS also plans to relaunch its Terphogz brand and expand the OzSun and value-oriented product lines in coming months, aiming to capture diverse market segments.

Financial Position and Outlook

At quarter end, ECS held $1.7 million in cash and cash equivalents, supplemented by $3.2 million in undrawn financing facilities, providing total available funding of approximately $4.9 million. Production and manufacturing costs for the quarter were $1.9 million, with related party payments totaling $174,000. The company’s financial discipline and access to capital offer flexibility to support growth initiatives amid evolving market conditions.

Looking ahead, ECS aims to capitalise on its operational momentum with key near-term catalysts including the commencement of commercial OzSun shipments into Germany, scaling up the AVANI AVA women’s health range, and growing export sales via New Zealand oil shipments. Managing Director Nan-Maree Schoerie emphasised the company’s confidence in navigating regulatory shifts that favour compliant, pharmaceutical-grade operators focused on quality and patient outcomes.